Literature DB >> 23079654

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Dominik Sturm1, Hendrik Witt, Volker Hovestadt, Dong-Anh Khuong-Quang, David T W Jones, Carolin Konermann, Elke Pfaff, Martje Tönjes, Martin Sill, Sebastian Bender, Marcel Kool, Marc Zapatka, Natalia Becker, Manuela Zucknick, Thomas Hielscher, Xiao-Yang Liu, Adam M Fontebasso, Marina Ryzhova, Steffen Albrecht, Karine Jacob, Marietta Wolter, Martin Ebinger, Martin U Schuhmann, Timothy van Meter, Michael C Frühwald, Holger Hauch, Arnulf Pekrun, Bernhard Radlwimmer, Tim Niehues, Gregor von Komorowski, Matthias Dürken, Andreas E Kulozik, Jenny Madden, Andrew Donson, Nicholas K Foreman, Rachid Drissi, Maryam Fouladi, Wolfram Scheurlen, Andreas von Deimling, Camelia Monoranu, Wolfgang Roggendorf, Christel Herold-Mende, Andreas Unterberg, Christof M Kramm, Jörg Felsberg, Christian Hartmann, Benedikt Wiestler, Wolfgang Wick, Till Milde, Olaf Witt, Anders M Lindroth, Jeremy Schwartzentruber, Damien Faury, Adam Fleming, Magdalena Zakrzewska, Pawel P Liberski, Krzysztof Zakrzewski, Peter Hauser, Miklos Garami, Almos Klekner, Laszlo Bognar, Sorana Morrissy, Florence Cavalli, Michael D Taylor, Peter van Sluis, Jan Koster, Rogier Versteeg, Richard Volckmann, Tom Mikkelsen, Kenneth Aldape, Guido Reifenberger, V Peter Collins, Jacek Majewski, Andrey Korshunov, Peter Lichter, Christoph Plass, Nada Jabado, Stefan M Pfister.   

Abstract

Glioblastoma (GBM) is a brain tumor that carries a dismal prognosis and displays considerable heterogeneity. We have recently identified recurrent H3F3A mutations affecting two critical amino acids (K27 and G34) of histone H3.3 in one-third of pediatric GBM. Here, we show that each H3F3A mutation defines an epigenetic subgroup of GBM with a distinct global methylation pattern, and that they are mutually exclusive with IDH1 mutations, which characterize a third mutation-defined subgroup. Three further epigenetic subgroups were enriched for hallmark genetic events of adult GBM and/or established transcriptomic signatures. We also demonstrate that the two H3F3A mutations give rise to GBMs in separate anatomic compartments, with differential regulation of transcription factors OLIG1, OLIG2, and FOXG1, possibly reflecting different cellular origins.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23079654     DOI: 10.1016/j.ccr.2012.08.024

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  747 in total

Review 1.  Molecular insights into pediatric brain tumors have the potential to transform therapy.

Authors:  Amar Gajjar; Stefan M Pfister; Michael D Taylor; Richard J Gilbertson
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

Review 2.  Recent advances in intradural spinal tumors.

Authors:  Muhammad M Abd-El-Barr; Kevin T Huang; Ziev B Moses; J Bryan Iorgulescu; John H Chi
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

3.  Nicotinamide metabolism regulates glioblastoma stem cell maintenance.

Authors:  Jinkyu Jung; Leo Jy Kim; Xiuxing Wang; Qiulian Wu; Tanwarat Sanvoranart; Christopher G Hubert; Briana C Prager; Lisa C Wallace; Xun Jin; Stephen C Mack; Jeremy N Rich
Journal:  JCI Insight       Date:  2017-05-18

4.  H3F3A K27M mutations in thalamic gliomas from young adult patients.

Authors:  Koki Aihara; Akitake Mukasa; Kengo Gotoh; Kuniaki Saito; Genta Nagae; Shingo Tsuji; Kenji Tatsuno; Shogo Yamamoto; Shunsaku Takayanagi; Yoshitaka Narita; Soichiro Shibui; Hiroyuki Aburatani; Nobuhito Saito
Journal:  Neuro Oncol       Date:  2013-11-26       Impact factor: 12.300

5.  Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors.

Authors:  Bernard L Marini; Lydia L Benitez; Andrew H Zureick; Ralph Salloum; Angela C Gauthier; Julia Brown; Yi-Mi Wu; Dan R Robinson; Chandan Kumar; Robert Lonigro; Pankaj Vats; Xuhong Cao; Katayoon Kasaian; Bailey Anderson; Brendan Mullan; Benjamin Chandler; Joseph R Linzey; Sandra I Camelo-Piragua; Sriram Venneti; Paul E McKeever; Kathryn A McFadden; Andrew P Lieberman; Noah Brown; Lina Shao; Marcia A S Leonard; Larry Junck; Erin McKean; Cormac O Maher; Hugh J L Garton; Karin M Muraszko; Shawn Hervey-Jumper; Jean M Mulcahy-Levy; Adam Green; Lindsey M Hoffman; Katie Dorris; Nicholas A Vitanza; Joanne Wang; Jonathan Schwartz; Rishi Lulla; Natasha Pillay Smiley; Miriam Bornhorst; Daphne A Haas-Kogan; Patricia L Robertson; Arul M Chinnaiyan; Rajen Mody; Carl Koschmann
Journal:  Transl Res       Date:  2017-08-10       Impact factor: 7.012

6.  Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.

Authors:  Balakrishna Koneru; Gonzalo Lopez; Ahsan Farooqi; Karina L Conkrite; Thinh H Nguyen; Shawn J Macha; Apexa Modi; Jo Lynne Rokita; Eduardo Urias; Ashly Hindle; Heather Davidson; Kristyn Mccoy; Jonas Nance; Vanda Yazdani; Meredith S Irwin; Shengping Yang; David A Wheeler; John M Maris; Sharon J Diskin; C Patrick Reynolds
Journal:  Cancer Res       Date:  2020-04-14       Impact factor: 12.701

7.  Simultaneous disruption of PRC2 and enhancer function underlies histone H3.3-K27M oncogenic activity in human hindbrain neural stem cells.

Authors:  Gerard L Brien; Raul Bardini Bressan; Craig Monger; Dáire Gannon; Eimear Lagan; Anthony M Doherty; Evan Healy; Hannah Neikes; Darren J Fitzpatrick; Orla Deevy; Vivien Grant; Maria-Angeles Marqués-Torrejón; Neza Alfazema; Steven M Pollard; Adrian P Bracken
Journal:  Nat Genet       Date:  2021-07-22       Impact factor: 38.330

8.  Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.

Authors:  Antje Wick; Tobias Kessler; Michael Platten; Christoph Meisner; Michael Bamberg; Ulrich Herrlinger; Jörg Felsberg; Astrid Weyerbrock; Kirsten Papsdorf; Joachim P Steinbach; Michael Sabel; Jan Vesper; Jürgen Debus; Jürgen Meixensberger; Ralf Ketter; Caroline Hertler; Regine Mayer-Steinacker; Sarah Weisang; Hanna Bölting; David Reuss; Guido Reifenberger; Felix Sahm; Andreas von Deimling; Michael Weller; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

9.  Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter.

Authors:  Rentian Wu; Qian Nie; Erin E Tapper; Calvin R Jerde; Garrett S Dunlap; Shikshya Shrestha; Tarig A Elraiyah; Steven M Offer; Robert B Diasio
Journal:  Cancer Res       Date:  2016-08-30       Impact factor: 12.701

10.  Human pontine glioma cells can induce murine tumors.

Authors:  Viola Caretti; A Charlotte P Sewing; Tonny Lagerweij; Pepijn Schellen; Marianna Bugiani; Marc H A Jansen; Dannis G van Vuurden; Anna C Navis; Ilona Horsman; W Peter Vandertop; David P Noske; Pieter Wesseling; Gertjan J L Kaspers; Javad Nazarian; Hannes Vogel; Esther Hulleman; Michelle Monje; Thomas Wurdinger
Journal:  Acta Neuropathol       Date:  2014-04-29       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.